Evaluation of Platelet Rich Plasma in the Management of Psoriasis

Psoriasis is a chronic immune-mediated disease affecting approximately 2–3% of general population. It isassociated with significant negative impact on patient’s physical and psychological quality of life along withvulnerability to co-morbidities such as cardiometabolic dysfunction, depression, and so on [1]. to evaluate theefficiency of platelet rich plasma (PRP) in the management of patients with chronic localized recalcitrant plaquepsoriasis.This was a prospective pilot study conducted on 30 cases with chronic localized recalcitrant psoriasisattended Dermatology, Venereology and Andrology outpatient clinics, Benha University Hospitalis. This study wasapproved by Dermatology, Venereology and Andrology Department and Ethics Commitee in the Faculty ofMedicine, Benha University. The study details were discussed with all patients and informed consents wereobtained from them before the begining of the study.PASI score had significantly decreased in group I after 8 and 16weeks of treatment when compared to the baseline (p =0.001). There was also significant decrease in PASI score betweenweek 8, 16 (p =0.0018). PASI score showed no significant difference in group II neither at week 8 nor 16 compared tobaseline (p =0.894).